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A commentary on
Probability of treatment following acute
decline in lung function in children with
cystic fibrosis is related to baseline pul-
monary function
by Morgan WJ, Wagener JS, Yegin A, Pasta
DJ, Millar SJ, Konstan MW. J Pediatr
(2013) 163(4):1152–7. doi:10.1016/ j.jpeds.
2013.05.013
Morgan et al. (1) concluded that cystic
fibrosis (CF) in children and adolescents
with a high baseline forced expiratory vol-
ume (FEV1) were less likely to have a ther-
apeutic intervention or slower rate of FEV1
decline after a single acute decline in FEV1
of 10%. This conclusion is not well sup-
ported due to the arbitrary criteria used
for defining a pulmonary exacerbation, as
explained below.
First, only a single low FEV1 value
defined an exacerbation. However, FEV1
measurements are notoriously variable
from test-to-test; Taylor-Robinson et al.
(2) showed that the baseline fluctuations
have a wide range of about 60%. FEV1
tests are sensitive to time of day, health
status, mood, tiredness, lack of sleep, med-
ical instruction, nutritional status, acute
comorbidities, and other factors Cystic
Fibrosis Foundation (3). Given that a single
FEV1 assessment was used, rather than the
average of repeated measurements on dif-
ferent days, evidence that the assessment
values were technically accurate.
Second, an exacerbation was defined
as a single 10% decline in FEV1 in the
above study without any explanation as to
why 10% was chosen nor why a range of
declines were not evaluated to determine
the sensitivity and specificity of different
criteria (by testing several criterion values
such as 5, 15, 20, and 25%). A threshold
of 10% is nearly within the noise level of
the FEV1 measurements (2, 4). This leaves
open the possibility that the findings in the
study would not hold if a slightly greater (or
smaller) value was used, such as 8 or 12%.
Furthermore, regarding the use of the
cutoff of 10%, there is no agreement on the
optimal cutoff for separating pulmonary
exacerbations from the large natural tech-
nical variations in FEV1 from test-to-test, a
variation that has been found to be higher
in CF without evidence of concomitant
changes in the severity of the condition (4,
5). National treatment guidelines (5) for
acute pulmonary exacerbations in CF was
based on the work of Fuchs et al. (6), a
clinical trial of DNAase that only inciden-
tally mentioned 10% as a criterion if 4 of
12 other signs or symptoms were present
in a population of adults and children. In
a more comprehensive study on children
under six years of age, Rabin et al. (7)
and Regelmann et al. (8) defined exacerba-
tions operationally by whether or not pul-
monologists decided to intensify treatment
using antibiotics. These authors found the
average FEV1 decline to be 20% in children
under 6 years of age, these investigators
proposed a refinement of the criterion to
15% or higher, rather than 10% suggested
by Fuchs et al. (6), under the condition
that a 15% decline would only be consid-
ered an exacerbation if two other clinical
signs were concurrent, such as increased
cough frequency, new crackles, or hemop-
tysis. Evidence on the best cutoff value is
consequently nearly absent and remains
to be determined. The most logical path
follow would be to first test the full range of
pulmonary decline criterion, perhaps from
0 to 30%, to determine the optimal crite-
rion, and then to conduct a focused study
on this value. The findings from such a
range analysis could be of great value in
helping further refine the criterion for an
exacerbation based on FEV1 decline, rather
than assuming a single value at this early
stage.
The study has many prominent strength
including well-defined hypotheses, very
large sample size, analysis by age group,
excellent statistical analysis, clearly pre-
sented findings, excellent flow of logic, and
others. However, due to the shortcomings
described above, we suggest further study
of the above critical questions before the
findings are implemented in practice.
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